Michael A. Savin, MD

Research Reports

Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non-Small Cell Lung Cancer Treatment Setting

02/15/2018

Michael A. Savin , MD;

Ravi Salgia , MD, PhD;

Blase Polite , MD;

Corey Shamah , MD;

Mark A. Socinski , MD;

Amanda Barry , MPH;

Kathy Lokay ;

Peter G. Ellis , MD;

Casey Mason ;

Ray Page , DO, PhD, FACOI, FASCO;

Natalie Dickson , MD;

Abstract: Despite clear clinical benefit and guideline recommendations for predictive biomarker testing and subsequent first-line targeted therapy treatment in patients with non–small cell lung cancer (NSCLC), there...

...

02/15/2018

Journal of Clinical Pathways

CIO 2022-20 Irreversible Electroporation for Recurrent Pelvic Metastases: Case Series and Literature Review

Purpose: Irreversible electroporation (IRE) is a nonthermal ablative technique that has potential safety advantages over thermal ablation in the treatment of patients with tumors near cri...

Jeffrey H. Savin , MD;

Michael A. Savin , MD;

Duncan A. Stevens ;

Brett J. Friedman , MPH;

10/18/2022